Uncategorized Archives - Page 8 of 87 - PsychedelicNewsWire (PNW)

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

TuesdayMay 03, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B In the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapies Delic Co-founder and CEO Matt Stang will continue his outreach to investors and other potential sources of industry financing when he presents an overview of the company’s operations and its outlook for the coming…

FridayApr 29, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery

Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics It seeks to achieve this through education, products and services, and research on psychedelics So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients Delic recognizes the potential of psychedelics and their application in therapeutics, hence its investment in research, civic education, and service delivery in this sector For many years, psychedelic drugs were frowned upon by society. This, along with psychedelics’ widespread popularity as recreational drugs in the 1960s and 70s,…

ThursdayApr 28, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeutic Cybin is currently developing CYB004 for the treatment of anxiety disorders The new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT. "In many studies, DMT has shown to be a promising and…

WednesdayApr 27, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds

Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered…

MondayApr 25, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances

Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal Delic recently received Health Canada authorization to obtain 60 grams of psilocybin…

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…

WednesdayApr 20, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine Back in October 2021, Delic…

MondayApr 18, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent application Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods," further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs. The application covers an array of inhalation delivery…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized